Author | Eleftherios P. Mamounas, MD, MPH

Articles

Neoadjuvant Therapy for Early-Stage Breast Cancer: A Model for Individualizing Outcomes and Tailoring Locoregional and Systemic Therapy

November 15, 2015

The biologic rationale for the initial evaluation of preoperative chemotherapy or neoadjuvant chemotherapy in patients with early-stage breast cancer was based on experimental and clinical observations regarding primary tumor cell growth and dissemination.

Adjuvant Exemestane Therapy After 5 Years of Tamoxifen: Rationale for the NSABP B-33 Trial

May 01, 2001

Tamoxifen (Nolvadex) has long been established as "standard" adjuvant therapy for receptor-positive, early-stage breast cancer. Results from clinical trials suggest that after approximately 5 years, tamoxifen may lose its

UFT/Leucovorin vs 5-FU/Leucovorin in Colon Cancer

October 01, 2000

Adjuvant chemotherapy has been shown to alter the natural history of resected colon cancer. Two regimens (fluorouracil [5-FU] plus leucovorin and 5-FU plus levamisole) have been found to prolong disease-free survival and overall survival in affected patients.

UFT Plus Calcium Folinate vs 5-FU Plus Calcium Folinate in Colon Cancer

July 01, 1999

Adjuvant chemotherapy has been shown to alter the natural history of resected colon cancer. Two regimens (5-fluorouracil [5-FU] plus calcium folinate and 5-FU plus levamisole [Ergamisol]) have been found to prolong